A new, minimally invasive prognostic test to improve treatment of prostate cancer, called Telo-PC, will be developed following the establishment of a collaborative agreement between 3D Signatures and Belgium-based MDxHealth. Prostate cancer diagnosis traditionally requires repeated invasive tissue biopsies, which do not guarantee the successful detection of tumor cells and may misdiagnose benign conditions as potentially dangerous, resulting in unnecessary surgeries. New, reliable, and minimally invasive diagnostic tools could help improve treatment decisions for prostate cancer patients. Telo-PC uses 3DS’ TeloView software platform, which enables a 3D analysis of the patients’ telomeres, the protective caps at the end of chromosomes. The technology analyzes the organization of the genome in circulating tumor cells to determine how the disease will progress and if a patient will respond to treatment, allowing doctors to establish an individualized treatment plan. “This is an excellent opportunity, combining our expertise in urological diagnostics with the innovative 3DS software platform, to evaluate an exciting technology that may improve the clinical management of patients with prostate cancer,” Jan Groen, CEO at MDxHealth, said in a press release. The two companies will share the costs of the study, while MDxHealth received an exclusive option from 3DS to negotiate a licensing agreement for the test.